Browsing by Author Neely, J

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 5 of 5
TitleAuthor(s)Issue DateViews
 
Assessment of Inflammation Biomarkers in Relation to Clinical Outcomes in Nivolumab-Treated Patients With Advanced Hepatocellular Carcinoma in CheckMate 040
Proceeding/Conference:Journal of Hepatology
Sangro, BMelero, IWadhawan, SFinn, RAbou-Alfa, GKCheng, ALYau, TCCFuruse, JPark, JWBoyd, ZTang, HTShen, YTschaika, MNeely, JEl-Khoueiry, A
2019
52
 
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial
Journal:JAMA Oncology
Yau, TCCKang, YKKim, TYEl-Khoueiry, ABSantoro, ASangro, BMelero, IKudo, MHou, MMMatilla, ATovoli, FKnox, JJHe, AREl-Rayes, BFAcosta-Rivera, MLim, HYNeely, JShen, YWisniewski, TAnderson, JHsu, C
2020
70
 
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Journal:Lancet
El-Khoueiry, ABSangro, BYau, TCCCrocenzi, TSKudo, MHsu, CKim, TYChoo, SPTrojan, JWelling, THMeyer, TKang, YKYeo, WChopra, AAnderson, JDela Cruz, CLang, LNeely, JTang, HDastani, HBMelero, I
2017
151
 
Phase 1/2 Safety and Antitumor Activity of Nivolumab in Patients With Advanced Hepatocellular Carcinoma: Interim Analysis of the CheckMate 040 Dose-Escalation Study
Proceeding/Conference:Liver Cancer
El-Khoueiry, ABSangro, BYau, TCCCrocenzi, TSWelling, TH, IIIYeo, WChopra, AAnderson, Jdela Cruz, CLang, LNeely, JMelero, I
2016
64
 
Safety and Antitumor Activity of Nivolumab (Nivo) in Patients (pts) with Advanced Hepatocellular Carcinoma (HCC): Interim Analysis of Dose-Expansion Cohorts from the Phase 1/2 CheckMate-040 Study
Proceeding/Conference:Liver Cancer
Sangro, BMelero, IYau, TCCHsu, CKudo, MCrocenzi, TSKim, TYChoo, SPTrojan, JMeyer, TKang, YKAnderson, Jdela Cruz, CLang, LNeely, JEl-Khoueiry, AB
2016
151
Showing results 1 to 5 of 5